Stifel raises target for Mirum Pharmaceuticals stock to USD 156.00

Published on 10/15/2026 at 22:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 176.24 million in the second quarter. Mirum Pharmaceuticals stock costs EUR 73.44 on October 15, 2026, up 3.04 percent on Nasdaq.

Analyst target and quarterly results

On October 15, 2026, Stifel lifted its target for Mirum Pharmaceuticals to USD 156.00.
Mirum's second-quarter revenue reached USD 176.24 million, up 37.90 percent year over year.
Mirum Pharmaceuticals stock costs EUR 73.44 at Lang & Schwarz on October 15, 2026 at 10:47 p.m. CEST, up 3.04 percent on Nasdaq versus the prior close of October 14, 2026.
The October 15, 2026 market capitalization was USD 5.3 billion, with a price-to-earnings ratio of minus 5.66.

MIRM, US6047491013, Illustration mit AI erstellt.

On October 15, 2026, Stifel raised its price target for Mirum Pharmaceuticals from USD 136.00 to USD 156.00 while maintaining a Buy rating, according to Investing.com. Against the Nasdaq price of USD 82.39 on October 15, 2026, the new target stands 89.34 percent higher. Mirum Pharmaceuticals was trading at EUR 73.44 at Lang & Schwarz on October 15, 2026 at 10:47 p.m. CEST, up 3.04 percent on Nasdaq versus the prior close of October 14, 2026.

Quarterly revenue outpaced estimates

For the second quarter of 2026, Mirum reported revenue of USD 176.24 million, up 37.90 percent from the year-earlier quarter and above the USD 166.33 million consensus estimate, according to MarketBeat. Adjusted earnings per share were not the driver of that quarter: reported earnings per share were minus USD 1.06, compared with a consensus loss of USD 0.74.

Price remains 36.62 percent below high

The Nasdaq price of USD 82.39 on October 15, 2026 sat between the 52-week low of USD 63.23 and high of USD 130.00. That places the stock 36.62 percent below its 52-week high. Trading volume was 603,432 shares against an average of 725,712 shares on the same date.

Valuation at USD 5.3 billion

Mirum's market capitalization was USD 5.3 billion on October 15, 2026, while its price-to-earnings ratio was minus 5.66. The Stifel target is the clearest dated valuation marker in the latest market context, but the company remains loss-making on the reported second-quarter earnings measure.

Comparison with peers

MIRM (Nasdaq, USD): plus 3.04 percent, P/E minus 5.66, market capitalization USD 5.3 billion
Vertex Pharmaceuticals (Nasdaq, USD): plus 2.06 percent, P/E 29.61, market capitalization USD 128.9 billion
BioMarin Pharmaceutical (Nasdaq, USD): plus 1.65 percent, P/E 143.72, market capitalization USD 10.8 billion

Mirum stock and the next session

Mirum's share price remains materially below its 52-week high even as the latest analyst target points to a higher valuation. The next market session will test whether the October 15 move holds after the after-hours indication.

Mirum Pharmaceuticals was trading at EUR 73.44 at Lang & Schwarz on October 15, 2026 at 10:47 p.m. CEST, up 3.04 percent on Nasdaq versus the prior close of October 14, 2026. The Nasdaq price was USD 82.39 on October 15, 2026 at 4:00 p.m. ET. The further course of trading is shown by the continuously updated real-time quote of Mirum Pharmaceuticals stock.